SCHEMBL4516916

SCHEMBL4516916

Cc1cc(S(N)(=O)=O)ccc1NC(=O)COc1ccc(Cl)cc1Oc1cc(C#N)cc(C#N)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 3/20 0.46
L3MBTL1 Q9Y468 4/20 0.46
HTT P42858 1/20 0.44
KCNH2 Q12809 1/20 0.44
MAPT P10636 2/20 0.43
POLB P06746 1/20 0.43
CA12 O43570 2/20 0.42
CA1 P00915 2/20 0.42
CA2 P00918 2/20 0.42
CA4 P22748 2/20 0.42
MAOB P27338 2/20 0.42
CA5A P35218 2/20 0.42
CA7 P43166 2/20 0.42
CA5B Q9Y2D0 2/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
ALDH1A1 P00352 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
LMNA P02545 1/20 0.41
CYP1A2 P05177 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4509266 0.97 SLC2A1 (0.48) SLC2A1L3MBTL1HTTKCNH2MAPT
SCHEMBL4527119 0.89 SLC22A12 (0.44) SLC2A1L3MBTL1HTTCA12CA1
SCHEMBL4517904 0.88 CA1 (0.49) L3MBTL1HTTMAPTPOLBCA12
SCHEMBL5623362 0.85 SLC2A1 (0.60) SLC2A1KCNH2MAPTPOLBCA12
SCHEMBL3937859 0.85 CA1 (0.43) SLC2A1MAPTPOLBCA12CA1
SCHEMBL4511385 0.85 L3MBTL1 (0.42) SLC2A1L3MBTL1HTTKCNH2MAPT
SCHEMBL3941729 0.84 CA1 (0.48) SLC2A1KCNH2CA12CA1CA2
SCHEMBL3940954 0.83 SLC2A1 (0.43) SLC2A1KCNH2MAPTPOLBCA12
SCHEMBL3945671 0.82 SLC2A1 (0.42) SLC2A1KCNH2MAPTCA12CA1
SCHEMBL5623733 0.82 SLC2A1 (0.58) SLC2A1KCNH2MAPTPOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264425-A1 CHEMICAL COMPOUNDS PFIZER LIMITED 2009-10-22 US claimed
EP-1831157-A2 NONNUCLEOSIDE INHIBITORS OF HIV-1 REVERSE TRANSCRIPTASE Pfizer Limited (GB) 2007-09-12 EP claimed
WO-2006067587-A2 NONNUCLEOSIDE INHIBITORS OF HIV-1 REVERSE TRANSCRIPTASE PFIZER LIMITED (GB) 2006-06-29 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264425-A1 CHEMICAL COMPOUNDS POLR2E, POLR2A, POLRMT SLC2A1 4452/4885L3MBTL1 1136/4885HTT 3536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.